Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Aakash Desai¹, Justin F Gainor², Aparna Hegde³, Alison M Schram⁴, Giuseppe Curigliano⁵, Sumanta Pal⁶, Stephen V Liu⁷, Balazs Halmos⁸, Roman Groisberg⁹, Enrique Grande¹⁰, Tomislav Dragovich¹¹, Marc Matrana¹², Neeraj Agarwal¹³, Sant Chawla¹⁴, Shumei Kato¹⁵, Gilberto Morgan¹⁶, Pashtoon M Kasi¹⁷, Benjamin Solomon¹⁸, Herbert H Loong¹⁹, Haeseong Park²⁰, Toni K Choueiri²¹, Ishwaria M Subbiah²², Naveen Pemmaraju²³, Vivek Subbiah^{24

25

26}; COVID19 and Cancer Clinical Trials Working Group

Affiliations

¹ Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
² Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
³ Department of Hematology and Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Department of Oncology and Hemato- Oncology, University of Milan and European Institute of Oncology, IRCCS, Milan, Italy.
⁶ Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
⁷ Department of Developmental Therapeutics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
⁸ Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, NY, USA.
⁹ Department of Melanoma/Sarcoma Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
¹⁰ Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
¹¹ Department of Hematology/Oncology, MD Anderson Banner Cancer Center, Gilbert, AZ, USA.
¹² Precision Cancer Therapies (Phase I) Research Program, Experimental Therapeutics, Ochsner, New Orleans, LA, USA.
¹³ Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
¹⁴ Sarcoma Oncology Center, Santa Monia, CA, USA.
¹⁵ Center for Personalized Cancer Therapy, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
¹⁶ Department of Oncology, Skåne University Hospital, Lund, Sweden.
¹⁷ Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Medicine, University of Iowa, Iowa City, IA, USA.
¹⁸ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
¹⁹ Department of Clinical Oncology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
²⁰ Division of Oncology, Department of Medicine, Washington University in St. Louis, St Louis, MO, USA.
²¹ Department of Medical Oncology, Dana- Farber Cancer Institute, Boston, MA, USA.
²² Department of Palliative, Rehabilitation & Integrative Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²³ Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²⁴ Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.
²⁵ Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.
²⁶ MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.

PMID: 33758378
PMCID: PMC7985918
DOI: 10.1038/s41571-021-00503-2

Published Erratum

Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Aakash Desai et al. Nat Rev Clin Oncol. 2021 May.

. 2021 May;18(5):320.

doi: 10.1038/s41571-021-00503-2.

Authors

Affiliations

¹ Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
² Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
³ Department of Hematology and Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Department of Oncology and Hemato- Oncology, University of Milan and European Institute of Oncology, IRCCS, Milan, Italy.
⁶ Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
⁷ Department of Developmental Therapeutics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
⁸ Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, NY, USA.
⁹ Department of Melanoma/Sarcoma Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
¹⁰ Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
¹¹ Department of Hematology/Oncology, MD Anderson Banner Cancer Center, Gilbert, AZ, USA.
¹² Precision Cancer Therapies (Phase I) Research Program, Experimental Therapeutics, Ochsner, New Orleans, LA, USA.
¹³ Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
¹⁴ Sarcoma Oncology Center, Santa Monia, CA, USA.
¹⁵ Center for Personalized Cancer Therapy, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
¹⁶ Department of Oncology, Skåne University Hospital, Lund, Sweden.
¹⁷ Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Medicine, University of Iowa, Iowa City, IA, USA.
¹⁸ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
¹⁹ Department of Clinical Oncology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
²⁰ Division of Oncology, Department of Medicine, Washington University in St. Louis, St Louis, MO, USA.
²¹ Department of Medical Oncology, Dana- Farber Cancer Institute, Boston, MA, USA.
²² Department of Palliative, Rehabilitation & Integrative Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²³ Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²⁴ Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.
²⁵ Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.
²⁶ MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.

PMID: 33758378
PMCID: PMC7985918
DOI: 10.1038/s41571-021-00503-2

No abstract available

PubMed Disclaimer

Erratum for

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. Desai A, et al. Nat Rev Clin Oncol. 2021 May;18(5):313-319. doi: 10.1038/s41571-021-00487-z. Epub 2021 Mar 15. Nat Rev Clin Oncol. 2021. PMID: 33723371 Free PMC article. Review.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Affiliations

Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Authors

Affiliations

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources